Velasco, R. http://orcid.org/0000-0003-3194-9406
Mercadal, S.
Vidal, N.
Alañá, M.
Barceló, M. I.
Ibáñez-Juliá, M. J.
Bobillo, S.
Caldú Agud, R.
García Molina, E.
Martínez, P.
Cacabelos, P.
Muntañola, A.
García-Catalán, G.
Sancho, J. M.
Camro, I.
Lado, T.
Erro, M. E.
Gómez-Vicente, L.
Salar, A.
Caballero, A. C.
Solé-Rodríguez, M.
Gállego Pérez-Larraya, J.
Huertas, N.
Estela, J.
Barón, M.
Barbero-Bordallo, N.
Encuentra, M.
Dlouhy, I.
Bruna, J.
Graus, F.
González-Barca, Eva
Climent, Fina
Bruixola, Gemma
Abrisqueta, Pau
Martin García-Sancho, Alejandro
Lopez Parra, Míriam
Escoda, Lourdes
Sorigué, Marc
Bataller, Luis
Córdoba, Raúl
González Sánchez, Miguel
Martino, Juan
Pardo-Moreno, Javier
,
Funding for this research was provided by:
Instituto de Salud Carlos III (PI1501303)
Article History
Received: 1 April 2020
Accepted: 26 May 2020
First Online: 10 June 2020
Compliance with ethical standards
:
: R.V. discloses membership on speaker bureau for Gilead and Novartis. A.S. discloses research funding and membership on advisory committees or speakers bureau for Roche, Celgene, Gilead or Janssen. F.G. holds a patent licensed to Euroimmun for the use of IgLON5 in an autoantibody test, for which he receives royalties, and receives honoraria from MedLink Neurology. The other authors declare no conflict of interest.
: The study was approved by the Institutional Ethical Committee of the coordinating center and, subsequently, by each participating center.